Molecular monitoring of chronic myeloid leukemia

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 62-68

  Hughes, Tim ^a   Branford, Susan ^b  

^a Division of Haematology   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; IMATINIB; INTERFERON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FOLLOW UP; HUMAN; NON INVASIVE MEASUREMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; DIAGNOSTIC PROCEDURE; GENETICS; PROGNOSIS; REVIEW;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR DIAGNOSTIC TECHNIQUES; PIPERAZINES; POLYMERASE CHAIN REACTION; PROGNOSIS; PYRIMIDINES;

EID: 0038700995     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50044     Document Type: Conference Paper

References (35)

1. Branford S, Hughes TP, Rudzski Z: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107:587-599, 1999
2. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
3. Buchdunger E, Zimmerman J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
4. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169-193, 2000
5. Bustin SA: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol 29:23-39, 2002
6. Cross NCP, Lin F, Chase A, et al: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936, 1993
7. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukaemia in mice by the P210BCR-ABL gene of the Philadelphia chromosome. Science 247:824-830, 1990
8. Druker BJ, Talpaz M, Resta D, et al: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
9. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
10. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069-1078, 1990
11. Goldman JM, Druker BJ: Chronic myeloid leukemia: Current treatment options. Blood 98:2039-42, 2001
12. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
13. Hochhaus A, Lin F, Reiter A et al: Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. Bone Marrow Transplant 17:S41-S44, 1996 (suppl 3)
14. Hochhaus A, Lin F, Reiter A, et al: Variable numbers of Bcr-Abl transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 91:126-131, 1995
15. Hochhaus A, Reiter A, Saussele S, et al: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62-66, 2000
16. Kantarjian H, Sawyers C, Hochhaus A, et al: Hemtologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
17. Kelliher MA, McLaughlin J, White ON, et al: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc Natl Acad Sci USA 87:6649-6653, 1990
18. Kurzrock R, Estrov Z, Kantarjian H, et al: Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16:1526-1531, 1998
19. Lin F, van Rhee F, Goldman JM, et al: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87:4473-4478, 1996
20. Lion T, Gaiger A, Henn T, et al: Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 9:1353-1360, 1995
21. Mensink E, van de Locht A, Schattenberg A, et al: Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102:768-774, 1998
22. Merx K, Muller MC, Kreil S, et al: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 9:1579-1583, 2002
23. Morley A: Quantifying leukemia. N Engl J Med 339:627-629, 1998
24. O'Brien SG, Guilhot F, Larson R, et al: The IRIS study: International randomized study of Interferon and low-dose Ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
25. Olavarria E, Kanfer E, Szydlo, et al: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97:1560-1565, 2001
26. Preudhomme C, Revillion F, Merlat A, et al: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia 13:957-964, 1999
27. Radich JP, Gooley T, Bryant E, et al: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 98:1701-1707, 2001
28. Saussele S, Weisser A, Muller MC, et al: Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia 14:2006-2010, 2000
29. Schoch C, Schnittger S, Bursch S, et al: Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 16:53-59, 2002
30. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
31. Stentoft J, Pallisgaard N, Kjeldsen E: Kinetics of Bcr-Abl fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 67:302-308, 2001
32. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002
33. Wang L, Pearson K, Pillitteri L, et al: Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 118:771-777, 2002
34. Wang YL, Bagg A, Pear W, et al: Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer 32:97-111, 2001
35. Westgard JO, Barry PL, Hunt MR et al: A multi-rule Shewart chart for quality control in clinical chemistry. Clin Chem 27:493-501, 1981